THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors

The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands ( www.guidetopharmacology.org ), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14750 . Nuclear hormone receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

[1]  Donald P. McDonnell,et al.  International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors , 2006, Pharmacological Reviews.

[2]  K. Korach,et al.  What's new in estrogen receptor action in the female reproductive tract. , 2016, Journal of molecular endocrinology.

[3]  Daniel M. Cohen,et al.  Nuclear Receptor Function through Genomics: Lessons from the Glucocorticoid Receptor , 2017, Trends in Endocrinology & Metabolism.

[4]  R. Touyz,et al.  Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications , 2017, Clinical science.

[5]  J. Carroll,et al.  Deciphering the divergent roles of progestogens in breast cancer , 2016, Nature Reviews Cancer.

[6]  K. Yamamoto,et al.  Glucocorticoid receptor control of transcription: precision and plasticity via allostery , 2017, Nature Reviews Molecular Cell Biology.

[7]  V. Craig Jordan,et al.  International Union of Pharmacology. LXIV. Estrogen Receptors , 2006, Pharmacological Reviews.

[8]  Y. Katsu,et al.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Evolution of the mineralocorticoid receptor: sequence, structure and function. , 2017, The Journal of endocrinology.

[9]  P. Driggers,et al.  Progesterone-Mediated Non-Classical Signaling , 2017, Trends in Endocrinology & Metabolism.

[10]  K. Korach,et al.  DNA Sequence Constraints Define Functionally Active Steroid Nuclear Receptor Binding Sites in Chromatin , 2017, Endocrinology.

[11]  S. Koochekpour,et al.  Androgen receptor splice variants and prostate cancer: From bench to bedside , 2017, Oncotarget.

[12]  M. Nanjan,et al.  Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. , 2017, Bioorganic chemistry.

[13]  Vincent Laudet,et al.  Overview of Nomenclature of Nuclear Receptors , 2006, Pharmacological Reviews.

[14]  E. Gonzalez-Sanchez,et al.  Nuclear Receptors in Acute and Chronic Cholestasis , 2015, Digestive Diseases.

[15]  M. Joëls,et al.  Brain mineralocorticoid receptor function in control of salt balance and stress-adaptation , 2017, Physiology & Behavior.